Search
Corifollitropin alfa
go.drugbank.com/drugs/DB09066ApprovedInvestigationalIn July 2014, Merck announced the receipt of a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application for this drug.
Calcitriol
go.drugbank.com/drugs/DB00136ApprovedInvestigationalNutraceutical[DB00146] undergoes hydroxylation to form calcitriol via 1α-hydroxylase (CYP27B1) activity [A26353]. Calcitriol is considered to be the most potent metabolite of vitamin D in humans [A3366].
Tenecteplase
go.drugbank.com/drugs/DB00031ApprovedInvestigationalTenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 1...
Ragweed pollen extract
go.drugbank.com/drugs/DB05368ApprovedWithdrawnRagweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. While traditional disease-modifying immunotherapeutics are administered by su...
Zanamivir
go.drugbank.com/drugs/DB00558ApprovedInvestigationalA guanido-neuraminic acid that is used to inhibit neuraminidase.
Eribulin
go.drugbank.com/drugs/DB08871ApprovedInvestigationalEribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated ...
Cefditoren
go.drugbank.com/drugs/DB01066ApprovedCefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
Bezlotoxumab
go.drugbank.com/drugs/DB13140ApprovedBezlotoxumab is a fully humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. First approved by the FDA on October 21, 2016, bezlotoxumab is used to reduce th...
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalCabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
Categories: Serotonin Receptor Agonists, Serotonin 5-HT1 Receptor Agonists